Does the Novartis acquisition foretell greater M&A activity for pharmaceutical stocks?
Swiss pharmaceutical firm Novartis’s pending bid to acquire majority ownership of Alcon, an eye care products maker, in a deal valued at about $40 billion, stood out against a backdrop of only 3% mergers-and-acquisitions growth across industry sectors globally for the first half of 2010. While we aren’t likely to see many more large-scale mergers,